AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in OW pregnant women
Number of subjects: 83
Study 34910118 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation in NW pregnant women
Number of subjects: 83
Study 34910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-fetal iron transfer in OW pregnant women
Number of subjects: 83
Study 34910118 — intervention group
Group type: COMPARATOR
Intervention: Maternal-fetal iron transfer in NW pregnant women
Number of subjects: 83
Study 34910118 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born to OW women
Number of subjects: 83
Study 34910118 — intervention group
Group type: COMPARATOR
Intervention: Infants born to NW women
Number of subjects: 83
Study 34910189 — intervention group
Group type: EXPERIMENTAL
Intervention: SUN + Ch (chocolate)
Number of subjects: 12
Study 34910189 — intervention group
Group type: EXPERIMENTAL
Intervention: SUN + P (apple puree)
Number of subjects: 12
Study 34910189 — intervention group
Group type: COMPARATOR
Intervention: Dual isotope method
Number of subjects: 12
Study 34910189 — intervention group
Group type: EXPERIMENTAL
Intervention: Free 13C-AA ileal digestibility
Number of subjects: 12
Study 34910278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1565
Study 34910278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1565
Study 34910278 — intervention group
Group type: COMPARATOR
Intervention: Event-free survival analysis for death, MACE, and bleeding
Number of subjects: 1565
Study 34910278 — intervention group
Group type: COMPARATOR
Intervention: Acute Coronary Syndrome (ACS)
Number of subjects: 1565
Study 34910295 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 212
Study 34910393 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib and bevacizumab maintenance therapy
Number of subjects: 44
Study 34910540 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameters derived from pretreatment dual-layer spectral-detector CT
Number of subjects: 0
Study 34910556 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine
Number of subjects: 190
Study 34910821 — intervention group
Group type: COMPARATOR
Intervention: Psychological interventions
Number of subjects: 37
Study 34910821 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological interventions
Number of subjects: 37
Study 34911163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34911359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily for up to 18 months
Number of subjects: 250
Study 34911463 — intervention group
Group type: EXPERIMENTAL
Intervention: REBOA (Resuscitative endovascular balloon occlusion of the aorta) as adjunct treatment to advanced cardiac life support
Number of subjects: 5
Study 34911463 — intervention group
Group type: EXPERIMENTAL
Intervention: REBOA
Number of subjects: 5
Study 34911471 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for life-time history of epilepsy or seizures using self-reported questionnaire data and diagnostic codes.
Number of subjects: 380
Study 34911471 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic validation through chart review for those who scored positive.
Number of subjects: 380
Study 34911471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of seizure disorders in acute psychiatric inpatients.
Number of subjects: 380
Study 34911479 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical fitness group (HPF)
Number of subjects: 28
Study 34911479 — intervention group
Group type: COMPARATOR
Intervention: Low physical fitness group (LPF)
Number of subjects: 28
Study 34911525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral-sciatic nerve block
Number of subjects: 155
Study 34911525 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided ankle block
Number of subjects: 155
Study 34911667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID, with optional up-titration to a maximum of 15 mg BID
Number of subjects: 66
Study 34911721 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy (specifics not provided)
Number of subjects: 20
Study 34911721 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 20
Study 34911791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 8406
Study 34911791 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (non-AF)
Number of subjects: 8406
Study 34911812 — intervention group
Group type: EXPERIMENTAL
Intervention: OA patients with painDETECT scores ≥19 (likely NP component)
Number of subjects: 72
Study 34911812 — intervention group
Group type: COMPARATOR
Intervention: OA patients with painDETECT scores ≤12 (without likely NP component)
Number of subjects: 72
Study 34911817 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-3500, a novel ATR kinase inhibitor, administered orally.
Number of subjects: 0
Study 34911956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate (TM), an orally bioavailable copper chelating agent.
Number of subjects: 0
Study 34911956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate (TM)
Number of subjects: 0
Study 34911956 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPK inhibition
Number of subjects: 0
Study 34911956 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of COX17 (copper chaperone)
Number of subjects: 0
Study 34911992 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunercept 200 mg/week plus standard RT/TMZ (Cohort 1)
Number of subjects: 10
Study 34911992 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunercept 400 mg/week plus standard RT/TMZ (Cohort 2)
Number of subjects: 10
Study 34912231 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and antimicrobial cosupplementations, specific dosages and duration not available
Number of subjects: 0
Study 34912347 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte HLA-DR (mHLA-DR) expression measurements on initial and third day after sepsis onset.
Number of subjects: 378
Study 34912347 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory treatment (not specified in detail).
Number of subjects: 378
Study 34912624 — intervention group
Group type: EXPERIMENTAL
Intervention: SIFFT-derived sacroiliac-leveling exercise (SIFFT-E)
Number of subjects: 72
Study 34912624 — intervention group
Group type: COMPARATOR
Intervention: Pelvic stabilization belt
Number of subjects: 72
Study 34912624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 34912624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of SIFFT-E and belt after one month
Number of subjects: 72
Study 34912839 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34912869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention for risk-based prevention of heart failure
Number of subjects: 0
Study 34912869 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34913153 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 257
Study 34913268 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth education program conducted by DNP students
Number of subjects: 0
Study 34913326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of CNSDs (≥4 weeks)
Number of subjects: 246
Study 34913326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of opioids (≥4 weeks)
Number of subjects: 246
Study 34913326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of CNSDs
Number of subjects: 246
Study 34913326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of opioids
Number of subjects: 246
Study 34913326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or more pain sites
Number of subjects: 246
Study 34913412 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly similar and competing visual scenes
Number of subjects: 0
Study 34913584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales (Vineland-3)
Number of subjects: 22
Study 34913611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 0
Study 34913611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 34913611 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0
Study 34913611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34913784 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (with or without exercise)
Number of subjects: 0
Study 34913784 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide combined with exercise
Number of subjects: 0
Study 34913784 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide alone
Number of subjects: 0
Study 34913784 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 34913855 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34914545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (group B, step-up dosing)
Number of subjects: 230
Study 34914616 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS text messages aimed at improving the redemption of WIC-approved foods for 12 weeks
Number of subjects: 0
Study 34914616 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS text messages
Number of subjects: 0
Study 34914658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia during Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
Number of subjects: 0
Study 34914727 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated VIA Classifier (AVC)
Number of subjects: 6000
Study 34914727 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 6000
Study 34914727 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 6000
Study 34914727 — intervention group
Group type: COMPARATOR
Intervention: Histopathological examination
Number of subjects: 6000
Study 34914727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' and providers' acceptability of AVC technology
Number of subjects: 6000
Study 34914826 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (4 cycles administered every 3 months during the first year after HCT)
Number of subjects: 21
Study 34915057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 0
Study 34915057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 0
Study 34915057 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of ritlecitinib and brepocitinib
Number of subjects: 0
Study 34915057 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with ritlecitinib and brepocitinib
Number of subjects: 0
Study 34915264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 97
Study 34915264 — intervention group
Group type: COMPARATOR
Intervention: No CPAP (Control)
Number of subjects: 97
Study 34915574 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg intravenous every 28 days for ≤7 years
Number of subjects: 71
Study 34915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the HAD scale
Number of subjects: 1565
Study 34915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the PSS-10 questionnaire
Number of subjects: 1565
Study 34915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the Short Form 12 Questionnaire (SF-12)
Number of subjects: 1565
Study 34915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lockdown assessment
Number of subjects: 1565
Study 34915900 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging combined with a pedometer; motivational messages to encourage walking and accountability messages to report pedometer steps.
Number of subjects: 44
Study 34915905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE)
Number of subjects: 20
Study 34915909 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered modular intervention based on cognitive behavioral therapy (CBT) for 8 weeks
Number of subjects: 60
Study 34915909 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control for 8 weeks, followed by access to the intervention for 8 weeks
Number of subjects: 60
Study 34915924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation Counseling for 4 weeks
Number of subjects: 0
Study 34915924 — intervention group
Group type: COMPARATOR
Intervention: Routine education in prenatal care and prenatal and childbirth classes
Number of subjects: 0
Study 34915984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Coandă effect
Number of subjects: 158
Study 34915984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of flail leaflet
Number of subjects: 158
Study 34915984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of both Coandă effect and flail leaflet
Number of subjects: 158
Study 34915984 — intervention group
Group type: COMPARATOR
Intervention: No Coandă or flail
Number of subjects: 158
Study 34915984 — intervention group
Group type: COMPARATOR
Intervention: Coandă effect only
Number of subjects: 158
Study 34915984 — intervention group
Group type: COMPARATOR
Intervention: Flail leaflet only
Number of subjects: 158
Study 34915984 — intervention group
Group type: COMPARATOR
Intervention: Both Coandă effect and flail leaflet
Number of subjects: 158
Study 34916316 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based research study ANRS Trans&HIV
Number of subjects: 0
Study 34916319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to adult mental health services (AMHS)
Number of subjects: 763
Study 34916319 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported problems
Number of subjects: 763
Study 34916319 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician ratings of illness severity
Number of subjects: 763
Study 34916319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication use
Number of subjects: 763
Study 34916324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 157
Study 34916326 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PLWH
Number of subjects: 400
Study 34916327 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intravenous S(+)-ketamine plus conventional anaesthesia
Number of subjects: 12000
Study 34916327 — intervention group
Group type: COMPARATOR
Intervention: Conventional anaesthesia only
Number of subjects: 12000
Study 34916627 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient dietary counseling
Number of subjects: 90
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation (MV)
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors or Inotropes (VIs)
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU Mortality
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance for process measures related to MV
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring delirium, sedation, and analgesia
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate transfusion of blood products
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of capnography
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of mortality
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital size and closed ICUs
Number of subjects: 4669
Study 34916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal Discharges (TDs)
Number of subjects: 4669
Study 34917079 — intervention group
Group type: EXPERIMENTAL
Intervention: Early myeloid-derived suppressor cells (eMDSCs) frequencies in engrafted patients at PT-Day 30
Number of subjects: 20
Study 34917079 — intervention group
Group type: EXPERIMENTAL
Intervention: High donor myeloid chimerism (HDMC) group
Number of subjects: 20
Study 34917079 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of eMDSCs and Tregs
Number of subjects: 20
Study 34917079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines associated with engraftment
Number of subjects: 20
Study 34917079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed chimeric eMDSCs and cytokines
Number of subjects: 20
Study 34917174 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus carboplatin/paclitaxel
Number of subjects: 0
Study 34917174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34917565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gentamicin regimen
Number of subjects: 0
Study 34917636 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of microalgae (photosynthetic cells) for oxygen supply to tissues, specific dosage and duration not mentioned.
Number of subjects: 0
Study 34917636 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 34918337 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotics (e.g. haloperidol, thiothixene)
Number of subjects: 6090
Study 34918337 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (e.g. risperidone, olanzapine, aripiprazole, quetiapine)
Number of subjects: 6090
Study 34918546 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0
Study 34918545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib
Number of subjects: 0
Study 34918545 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34918624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendyne valve (TMVR)
Number of subjects: 20
Study 34918637 — intervention group
Group type: EXPERIMENTAL
Intervention: Single acupoint group (Shenmen HT7)
Number of subjects: 333
Study 34918637 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatibility acupoint group (Shenmen HT7, Baihui DU20, Sanyinjiao SP6)
Number of subjects: 333
Study 34918637 — intervention group
Group type: COMPARATOR
Intervention: Nonacupoint control group
Number of subjects: 333
Study 34918637 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 333
Study 34918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (HbA1c ≥6.5% or history of diabetes)
Number of subjects: 4796
Study 34918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetes (HbA1c 6.0%-6.4%)
Number of subjects: 4796
Study 34918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes treated with insulin
Number of subjects: 4796
Study 34918855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean diabetes
Number of subjects: 4796
Study 34918855 — intervention group
Group type: COMPARATOR
Intervention: Normal HbA1c (<6.0%)
Number of subjects: 4796
Study 34919824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib, oral administration once per day
Number of subjects: 62
Study 34920345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 100
Study 34920345 — intervention group
Group type: COMPARATOR
Intervention: Neither SXB nor stimulants
Number of subjects: 100
Study 34920345 — intervention group
Group type: COMPARATOR
Intervention: Sodium oxybate (SXB) with or without stimulants
Number of subjects: 100
Study 34920728 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 2
Study 34920728 — intervention group
Group type: COMPARATOR
Intervention: Non-septic patients
Number of subjects: 2
Study 34920739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 192
Study 34920739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 34920739 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss with Metformin
Number of subjects: 192
Study 34920739 — intervention group
Group type: COMPARATOR
Intervention: Weight loss with Placebo
Number of subjects: 192
Study 34920917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily
Number of subjects: 25
Study 34920946 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 18
Study 34921021 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1)
Number of subjects: 147
Study 34921052 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative plasma levels of cytokines (IL-10, IL-1β, vascular endothelial growth factor, IL12/IL23p40)
Number of subjects: 162
Study 34921052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prearthrotomy synovial fluid IL-10 levels
Number of subjects: 162
Study 34921052 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of persistent pain at 6 months post TKA
Number of subjects: 162
Study 34921084 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D
Number of subjects: 45
Study 34921084 — intervention group
Group type: EXPERIMENTAL
Intervention: 48,000 IU vitamin D
Number of subjects: 45
Study 34921084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34921084 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (24,000 IU, 48,000 IU, and placebo)
Number of subjects: 45
Study 34921238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 98
Study 34921324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid 5-mL/kg body weight volume expansion
Number of subjects: 38
Study 34921355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4581
Study 34921355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4581